Pleasants, Roy A. published the artcileGlycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease, Synthetic Route of 142-90-5, the main research area is review chronic obstructive pulmonary disease glycopyrrolate LAMA nebulizer; anticholinergics; bronchodilators; chronic obstructive pulmonary disease; drug development and approval; inhalers; pharmaceutical care.
Objective: To review the pharmacol., efficacy, and safety of the first nebulized long-acting muscarinic antagonist (LAMA), glycopyrrolate (GLY)/eFlow closed system (CS) nebulizer, approved for maintenance treatment of chronic obstructive pulmonary disease (COPD). Data Sources: A PubMed search was conducted (Jan. 2000 to July 2018) using the following terms/phrases: nebulized glycopyrrolate, inhalation devices in COPD, long-acting muscarinic antagonists COPD, and COPD survey. Retrieved articles were reviewed to identify addnl. references Study Selection and Data Extraction: Primary and review articles on GLY/eFlow CS and other treatment options for patients with COPD were selected. Data Synthesis: Guidelines recommend the use of LAMAs, alone or in combination with long-acting β2-agonists, as maintenance therapy for the majority of patients with COPD. With the range of different devices and bronchodilators now available, treatment can be tailored based on individual needs. The eFlow CS nebulizer delivers GLY rapidly over a 2- to 3-min period and provides bronchodilation within 30 min, lasting 12 h. Phase 2 dose-finding and phase 3 studies demonstrated sustained statistically significant and clin. important improvements in pulmonary function and patient-reported outcomes with GLY/eFlow CS. Relevance to Patient Care and Clin. Practice: GLY/eFlow CS provides a novel, portable, efficient, and rapid drug delivery system. Conclusions: The recently approved GLY/eFlow CS drug-device combination provides a viable treatment option for patients with COPD, particularly those with conditions that may impair proper use of traditional handheld inhalers.
Annals of Pharmacotherapy published new progress about Bronchodilators. 142-90-5 belongs to class esters-buliding-blocks, name is Dodecyl 2-methylacrylate, and the molecular formula is C16H30O2, Synthetic Route of 142-90-5.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics